Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Public ClinicalTrials.gov record NCT06915753. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Study identification
- NCT ID
- NCT06915753
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Tyra Biosciences, Inc
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
- Advanced Solid Tumors
- FGF19 Gene Amplification
- FGF19 Gene Overexpression
- FGFR Gene Alterations
- FGFR Gene Amplification
- FGFR3 Gene Alteration
- FGFR3 Gene Fusions
- FGFR3 Gene Mutation
- FGFR4 Gene Fusions
- FGFR4 Gene Mutation
- Locally Advanced Unresectable Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
- Solid Tumor, Adult
- Solid Tumors
Interventions
- TYRA-430 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2025
- Primary completion
- Dec 31, 2027
- Completion
- Aug 31, 2028
- Last update posted
- Nov 19, 2025
2025 – 2028
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| UCSF Medical Center at Mount Zion | San Francisco | California | 94158 | Recruiting |
| Stanford Cancer Institute | Stanford | California | 94305 | Recruiting |
| The University of Kansas Medical Center | Westwood | Kansas | 66205 | Recruiting |
| John Hopkins University | Baltimore | Maryland | 21205 | Recruiting |
| Mass General Cancer Center | Boston | Massachusetts | 02114 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Columbia University Irving Medical Center | New York | New York | 10043 | Recruiting |
| Sarah Cannon Research Institute Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06915753, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06915753 live on ClinicalTrials.gov.